Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron J Keizer

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Clinical Pharmacokinetics|January 24, 2019
Personalized Tuberculosis Treatment Through Model-Informed Dosing of RifampicinStijn W van Beek, Rob Ter Heine, Ron J Keizer, et al.
Journal of Clinical Pharmacology|January 26, 2011
Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitorRon J Keizer, Ilona Kleine Budde, Paul F W Sprengers, et al.
The AAPS Journal|March 10, 2011
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studiesRon J Keizer, Y Funahashi, T Semba, et al.
European Journal of Clinical Pharmacology|November 23, 2006
Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive studyAdrianne Faber, Ron J Keizer, Paul B van den Berg, et al.
Therapeutic Drug Monitoring|March 28, 2022
Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation TrialMarith I Francke, Dennis A Hesselink, Louise M Andrews, et al.
Clinical Pharmacokinetics|March 27, 2024
Personalized Antifungal Therapy Through Model-Informed Precision Dosing of PosaconazoleAnouk M E Jansen, Kim Snijdelaar, Ron J Keizer, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 28, 2023
Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning modelJasmine H Hughes, Dominic M H Tong, Vanessa Burns, et al.
Pharmacology Research & Perspectives|June 4, 2015
Incorporation of concentration data below the limit of quantification in population pharmacokinetic analysesRon J Keizer, Robert S Jansen, Hilde Rosing, et al.
Transplantation and Cellular Therapy|March 30, 2021
The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant DisordersBeth Apsel Winger, Praveen Shukla, Sandhya Kharbanda, et al.
Journal of Pharmaceutical Sciences|April 15, 2011
An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavirRob ter Heine, Robert A B Van Waterschoot, Ron J Keizer, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Clinical Pharmacokinetics|January 24, 2019
Personalized Tuberculosis Treatment Through Model-Informed Dosing of RifampicinStijn W van Beek, Rob Ter Heine, Ron J Keizer, et al.
Journal of Clinical Pharmacology|January 26, 2011
Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitorRon J Keizer, Ilona Kleine Budde, Paul F W Sprengers, et al.
The AAPS Journal|March 10, 2011
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studiesRon J Keizer, Y Funahashi, T Semba, et al.
European Journal of Clinical Pharmacology|November 23, 2006
Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive studyAdrianne Faber, Ron J Keizer, Paul B van den Berg, et al.
Therapeutic Drug Monitoring|March 28, 2022
Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation TrialMarith I Francke, Dennis A Hesselink, Louise M Andrews, et al.
Clinical Pharmacokinetics|March 27, 2024
Personalized Antifungal Therapy Through Model-Informed Precision Dosing of PosaconazoleAnouk M E Jansen, Kim Snijdelaar, Ron J Keizer, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 28, 2023
Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning modelJasmine H Hughes, Dominic M H Tong, Vanessa Burns, et al.
Pharmacology Research & Perspectives|June 4, 2015
Incorporation of concentration data below the limit of quantification in population pharmacokinetic analysesRon J Keizer, Robert S Jansen, Hilde Rosing, et al.
Transplantation and Cellular Therapy|March 30, 2021
The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant DisordersBeth Apsel Winger, Praveen Shukla, Sandhya Kharbanda, et al.
Journal of Pharmaceutical Sciences|April 15, 2011
An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavirRob ter Heine, Robert A B Van Waterschoot, Ron J Keizer, et al.
Pageof 6